Literature DB >> 18723211

Detailed analysis of Charlson comorbidity score as predictor of mortality after radical prostatectomy.

Michael Froehner1, Rainer Koch, Rainer J Litz, Sven Oehlschlaeger, Lars Twelker, Oliver W Hakenberg, Manfred P Wirth.   

Abstract

OBJECTIVES: To investigate the prognostic significance of the individual conditions contributing to the Charlson comorbidity score in patients selected for radical prostatectomy.
METHODS: A total of 1910 consecutive patients who underwent radical prostatectomy from 1992 to 2004 were studied. The Charlson score and its contributing single conditions were analyzed, and the patients were stratified into 3 age groups. Comorbid (noncancer), competing (nonprostate cancer), and overall mortality were used as the study endpoints. Mantel-Haenszel hazard ratios and Kaplan-Meier survival curves were calculated. Comparisons were made using the log-rank test.
RESULTS: Eleven comorbid conditions were significant predictors of any type of mortality in the different age groups. Eight conditions (congestive heart failure, peripheral vascular disease, cerebrovascular disease, diabetes, hemiplegia, moderate or severe renal disease, diabetes with end organ damage, moderate or severe liver disease, and metastatic solid tumor) were significant predictors of overall mortality. Two conditions (moderate or severe renal disease and metastatic solid tumor) were significant predictors of overall mortality in patients <63 years old. Five conditions (myocardial infarction, congestive heart failure, hemiplegia, moderate or severe renal disease, and diabetes with end organ damage) were significant predictors in patients aged 63-69 years, and 3 (peripheral vascular disease, cerebrovascular disease, and moderate or severe liver disease) were significant in patients aged >or=70 years.
CONCLUSIONS: In patients selected for radical prostatectomy, the Charlson score can also predict the mortality risk in those >70 years of age. The selection for good risks alters, however, the prognostic weight of the individual comorbid diseases in this age group.

Entities:  

Mesh:

Year:  2008        PMID: 18723211     DOI: 10.1016/j.urology.2008.05.037

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  8 in total

1.  [Social gradient of PSA screening? 8 years follow up from the cancer registry of the tumor center in Regensburg].

Authors:  T Klotz; M J Mathers; M Gerken; M Klinkhammer-Schalke; F Hofstädter
Journal:  Urologe A       Date:  2010-12       Impact factor: 0.639

2.  Plasma metabolomic profiles predict near-term death among individuals with lower extremity peripheral arterial disease.

Authors:  Chiang-Ching Huang; Mary M McDermott; Kiang Liu; Ching-Hua Kuo; San-Yuan Wang; Huimin Tao; Yufeng Jane Tseng
Journal:  J Vasc Surg       Date:  2013-05-17       Impact factor: 4.268

3.  Oncological and functional outcomes in patients over 70 years of age treated with robotic radical prostatectomy: a propensity-matched analysis.

Authors:  Pratik M S Gurung; Bokai Wang; Stephen Hassig; Jasmine Wood; Elizabeth Ellis; Changyong Feng; Ahmed E Ghazi; Jean V Joseph
Journal:  World J Urol       Date:  2020-06-14       Impact factor: 4.226

Review 4.  Optimal management of recurrent prostate cancer in older patients.

Authors:  Elizabeth R Kessler; Thomas W Flaig
Journal:  Drugs Aging       Date:  2012-11       Impact factor: 3.923

5.  Patients with localised prostate cancer (t1 - t2) show improved overall long-term survival compared to the normal population.

Authors:  Michael J Mathers; Stephan Roth; Monika Klinkhammer-Schalke; Michael Gerken; Ferdinand Hofstaedter; Stefan Wilm; Theodor Klotz
Journal:  J Cancer       Date:  2011-02-08       Impact factor: 4.207

6.  Association of the Charlson comorbidity index with renal outcome and all-cause mortality in antineutrophil cytoplasmatic antibody-associated vasculitis.

Authors:  Shachaf Ofer-Shiber; Yair Molad
Journal:  Medicine (Baltimore)       Date:  2014-11       Impact factor: 1.889

7.  Age-adjusted Charlson Comorbidity Index as a prognostic factor for radical prostatectomy outcomes of very high-risk prostate cancer patients.

Authors:  Jae Won Park; Dong Hoon Koh; Won Sik Jang; Joo Yong Lee; Kang Su Cho; Won Sik Ham; Koon Ho Rha; Woo Hee Jung; Sung Joon Hong; Young Deuk Choi
Journal:  PLoS One       Date:  2018-06-20       Impact factor: 3.240

8.  Charlson comorbidity index is an important prognostic factor for long-term survival outcomes in Korean men with prostate cancer after radical prostatectomy.

Authors:  Joo Yong Lee; Dae Hun Lee; Nam Hoon Cho; Koon Ho Rha; Young Deuk Choi; Sung Joon Hong; Seung Choul Yang; Kang Su Cho
Journal:  Yonsei Med J       Date:  2014-03       Impact factor: 2.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.